GIGABYTE
15.2.2024 18:31:29 CET | Business Wire | Press release
GIGABYTE Technology, an IT pioneer whose focus is to advance global industries through cloud and AI computing systems, is coming to MWC 2024 with its next-generation servers empowering telcos, cloud service providers, enterprises, and SMBs to swiftly harness the value of 5G and AI. Featured is a cutting-edge AI server boasting AMD Instinct™ MI300X 8-GPU, and a comprehensive AI/HPC server series supporting the latest chip technology from AMD, Intel, and NVIDIA. The showcase will also feature integrated green computing solutions excelling in heat dissipation and energy reduction.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240215917651/en/
Inviting the AI-powered 5G Era, GIGABYTE will Present Next-Gen Servers for AI HPC, Telecom, and Green Computing Solutions at MWC 2024
Continuing the booth theme “Future of COMPUTING”, GIGABYTE's presentation will cover servers for AI/HPC, RAN and Core networks, modular edge platforms, all-in-one green computing solutions, and AI-powered self-driving technology. The exhibits will demonstrate how industries extend AI applications from cloud to edge and terminal devices through 5G connectivity, expanding future opportunities with faster time to market and sustainable operations. The showcase spans from February 26th to 29th at Booth #5F60, Hall 5, Fira Gran Via, Barcelona.
Tomorrow’s AI Supercomputers
The demand for AI-ready infrastructure and high-speed storage is escalating within the 5G framework, business operations, and academic research, driven by the exponential growth in data volume and the complexity of AI models. GIGABYTE will showcase its latest series of AI/HPC servers and an all-flash array (AFA) storage server. These servers support AMD Instinct™ MI300X OAM GPU modules, MI300A APUs, 5th Gen Intel® Xeon® Scalable Processors, NVIDIA HGX H100 8-GPU, and NVIDIA Grace Hopper Superchip, also leveraging the next-gen HBM3, ensuring hyper-speed data transmission. This technological leap is poised to advance exascale AI workloads and real-time big data analysis.
Flexible Server Architectures for the AI-enabled 5G Networks
The massive deployment of 5G applications requires flexibly configured digital infrastructure capable of supporting diverse IT ecosystems. GIGABYTE will introduce one of its modular edge platforms designed to manage a wide range of workloads, including networking, AI inferencing, and cloud computing. This platform offers seamless upgrades to accommodate multi-generational chip technologies and components, ensuring agile adaptation to rapid market changes with minimized maintenance costs.
In response to the rising demand for 5G and AI applications across businesses of varying scales, GIGABYTE will introduce its latest servers tailored for RAN and Core networks. These servers offer robust performance, catering to a range of computing needs from large-scale cloud-native workloads and telecom services to SMB IT operations. They excel in energy efficiency and provide expansion opportunities for AI-accelerated computing.
Sustainable AI and Cloud Computing Ensures Optimized TCO
At MWC, GIGABYTE is set to showcase its comprehensive all-in-one green computing solution, featuring a large-scale immersion cooling tank and two immersion-ready servers tailored for AI and cloud computing. The exhibit emphasizes their remarkable heat-dissipation capabilities and significantly lower power consumption. These features translate into a favorable total cost of ownership (TCO), highlighting GIGABYTE's commitment to sustainable and efficient computing solutions.
Future-Proof E-mobility Driven by Edge AI
Leveraging the 5G network and advanced AI algorithms, GIGABYTE's autonomous vehicle technology offers an exceptionally intelligent driving experience driven by edge AI. The high-speed data transmission performance ensures that GIGABYTE's Advanced Driver Assistance Systems (ADAS) and telematics efficiently process vast amounts of data from cameras, radars, and ultrasonic sensors. This enables the system to deliver precise real-time driving decisions, even in complex road conditions.
At GIGABYTE’s booth, enterprises can explore innovative and flexible computing solutions aligning with their strategies to gain a competitive edge in the AI-accelerated 5G future.
Visit GIGABYTE’s MWC event page.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240215917651/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom